Story perspectives

Baxdrostat Slashes Albumin 55% in CKD Trial, Raises Potassium

5/10/2026

Summary

Story summary

A Phase 2 trial showed baxdrostat cut urine albumin by about 55 % versus placebo, suggesting kidney protection.
The double-blind, placebo-controlled study enrolled 195 U.S. adults with chronic kidney disease and uncontrolled hypertension.
High potassium appeared in 41 % of baxdrostat patients versus 5 % on placebo, while serious adverse events occurred in 9 % versus 3 %.
AstraZeneca will test baxdrostat with dapagliflozin in Phase 3 trials for kidney and cardiovascular outcomes.

1 of 1

Story summary

A Phase 2 trial showed baxdrostat cut urine albumin by about 55 % versus placebo, suggesting kidney protection.
The double-blind, placebo-controlled study enrolled 195 U.S. adults with chronic kidney disease and uncontrolled hypertension.
High potassium appeared in 41 % of baxdrostat patients versus 5 % on placebo, while serious adverse events occurred in 9 % versus 3 %.
AstraZeneca will test baxdrostat with dapagliflozin in Phase 3 trials for kidney and cardiovascular outcomes.